Acute Viral Infections of the Central Nervous System in Immunocompetent Adults: Diagnosis and Management
详细信息 查看全文
- 作者：Marie Studahl (1) (7)
Lars Lindquist (2)
Britt-Marie Eriksson (3)
G?ran Günther (3)
Malin Bengner (4)
Elisabeth Franzen-R?hl (8)
Jan Fohlman (5)
Tomas Bergstr?m (6)
Elisabeth Aurelius (8) - 刊名：Drugs
- 出版年：2013
- 出版时间：February 2013
- 年：2013
- 卷：73
- 期：2
- 页码：131-158
- 全文大小：706KB
- 参考文献：1. Rantalaiho T, F?rkkil? M, Vaheri A, et al. Acute encephalitis from 1967 to 1991. J Neurol Sci. 2001;184(2):169-7. CrossRef
2. Davison KL, Crowcroft NS, Ramsay ME, et al. Viral encephalitis in England, 1989-998: what did we miss? Emerg Infect Dis. 2003;9(2):234-0. CrossRef
3. Kupila L, Vuorinen T, Vainionp?? R, et al. Etiology of aseptic meningitis and encephalitis in an adult population. Neurology. 2006;66(1):75-0. CrossRef
4. Raschilas F, Wolff M, Delatour F, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis. 2002;35(3):254-0. CrossRef
5. McGrath N, Anderson NE, Croxson MC, et al. Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. J Neurol Neurosurg Psychiatry. 1997;63(3):321-. CrossRef
6. Domingues RB, Tsanaclis AM, Pannuti CS, et al. Evaluation of the range of clinical presentations of herpes simplex encephalitis by using polymerase chain reaction assay of cerebrospinal fluid samples. Clin Infect Dis. 1997;25(1):86-1. CrossRef
7. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861-1. CrossRef
8. Persson A, Bergstr?m T, Lindh M, et al. Varicella zoster virus CNS disease: viral load, clinical manifestations and sequels. J Clin Virol. 2009;46(3):249-3. CrossRef
9. Franzen-R?hl E, Tiveljung-Lindell A, Grillner L, et al. Increased detection rate in diagnosis of herpes simplex virus type 2 meningitis by real-time PCR using cerebrospinal fluid samples. J Clin Microbiol. 2007;45(8):2516-0. CrossRef
10. Mailles A, Stahl JP. Infectious encephalitis in France in 2007: a national prospective study. Clin Infect Dis. 2009;49(12):1838-7. CrossRef
11. Graner?d J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10(12):835-4. CrossRef
12. Franzen-R?hl E, Larsson K, Skoog E, et al. High diagnostic yield by CSF-PCR for entero- and herpes simplex viruses and TBEV serology in adults with acute aseptic meningitis in Stockholm. Scand J Infect Dis. 2008;40(11-2):914-1. CrossRef
13. Studahl M, Hagberg, Rekabdar E, et al. Hematogenously spread herpesviruses are detected as frequently as neuronally spread herpesviruses in cerebrospinal fluid by polymerase chain reaction assay. Clin Infect Dis. 1999;29(1):216-. CrossRef
14. Weinberg A, Bloch KC, Li S, Tang YW, Palmer M, Tyler KL. Dual infections of the central nervous system with Epstein–Barr virus. J Infect Dis. 2005;191(2):234-. CrossRef
15. Kleines M, Schiefer J, Stienen A, et al. Expanding the spectrum of neurological disease associated with Epstein–Barr virus activity. Eur J Clin Microbiol Infect Dis. 2011;30(12):1561-. CrossRef
16. Martelius T, Lappalainen M, Palom?ki M, et al. Clinical characteristics of patients with Epstein–Barr virus in cerebrospinal fluid. BMC Infect Dis. 2011;11:281. CrossRef
17. Leong HN, Tuke PW, Tedder RS, et al. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol. 2007;79(1):45-1. CrossRef
18. Ward KN, Leong HN, Thiruchelvam AD, et al. Human herpesvirus 6 DNA levels in cerebrospinal fluid due to primary infection differ from those due to chromosomal viral integration and have implications for diagnosis of encephalitis. J Clin Microbiol. 2007;45(4):1298-04. CrossRef
19. Forsgren M, Sk?ldenberg B, Jeansson S, et al. Serodiagnosis of herpes encephalitis by indirect enzyme-linked immunosorbent assay, experience from a Swedish trial. Serodiagn Immunother Infect Dis. 1989;3(4):259-1. CrossRef
20. Gunther G, Haglund M, Lindquist L, et al. Intrathecal IgM, IgA and IgG antibody response in tick-borne encephalitis: long-term follow-up related to clinical course and outcome. Clin Diagn Virol. 1997;8(1):17-9. CrossRef
21. Gregoire SM, van Pesch V, Goffette S, et al. Polymerase chain reaction analysis and oligoclonal antibody in the cerebrospinal fluid from 34 patients with varicella-zoster virus infection of the nervous system. J Neurol Neurosurg Psychiatry. 2006;77(8):938-2. CrossRef
22. Solomon T, Michael BD, Smith PE, Sanderson F, Davies NW, Hart IJ, et al. Management of suspected viral encephalitis in adults. Association of British Neurologists and British Infection Association National Guidelines. J Infect. 2012;64(4):347-3. CrossRef
23. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47(3):303-7. CrossRef
24. Aurelius E, Johansson B, Sk?ldenberg B, et al. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet. 1991;337(8735):189-2. CrossRef
25. Aurelius E, Johansson B, Sk?ldenberg B, et al. Encephalitis in immunocompetent patients due to herpes simplex virus type 1 or 2 as determined by type-specific polymerase chain reaction and antibody assays of cerebrospinal fluid. J Med Virol. 1993;39(3):179-6. CrossRef
26. Guffond T, Dewilde A, Lopert PE, et al. Significance and clinical relevance of the detection of herpes simplex virus DNA by the polymerase chain reaction in cerebrospinal fluid from patients with presumed encephalitis. Clin Infect Dis. 1994;18(5):744-. CrossRef
27. Studahl M, Bergstr?m T, Hagberg L. Acute viral encephalitis in adults: a prospective study. Scand J Infect Dis. 1998;30(3):215-0. CrossRef
28. Puchhammer-St?ckl E, Presterl E, Aberle S, et al. Screening for possible failure of herpes simplex virus PCR in cerebrospinal fluid for the diagnosis of herpes simplex encephalitis. J Med Virol. 2001;64(4):531-. CrossRef
29. Weil AA, Glaser CA, Amad Z, et al. Patients with suspected herpes simplex encephalitis: rethinking an initial negative polymerase chain reaction result. Clin Infect Dis. 2002;34(8):1154-. CrossRef
30. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342(12):844-0. CrossRef
31. Kennedy PG. A retrospective analysis of forty-six cases of herpes simplex encephalitis seen in Glasgow between 1962 and 1985. Q J Med. 1988;68(255):533-0.
32. Sk?ldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes simplex encephalitis: randomised multicentre study in consecutive Swedish patients. Lancet. 1984;2(8405):707-1. CrossRef
33. Whitley RJ, Soong SJ, Linneman C, et al. Herpes simplex encephalitis: clinical assessment. JAMA. 1982;247(3):317-0. CrossRef
34. Utley TFM, Ogden JA, Gibb A, McGrath N, Anderson NE. The long-term neuro-psychological outcome of herpes simplex encephalitis in a series of unselected survivors. Neuropsychiatry Neuropsychol Behav Neurol. 1997;10:180-.
35. Gordon B, Selnes OA, Hart J Jr, Hanley DF, Whitley RJ. Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis. Arch Neurol. 1990;47:646-. CrossRef
36. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986;314(3):144-. CrossRef
37. Hjalmarsson A, Blomqvist P, Sk?ldenberg B. Herpes simplex encephalitis in Sweden, 1990-001: incidence, morbidity, and mortality. Clin Infect Dis. 2007;45(7):875-0. CrossRef
38. Dennett C, Cleator GM, Klapper PE. HSV-1 and HSV-2 in herpes simplex encephalitis: a study of sixty-four cases in the United Kingdom. J Med Virol. 1997;53(1):1-. CrossRef
39. Vandvik B, Sk?ldenberg B, Forsgren M, et al. Long-term persistence of intrathecal virus-specific antibody responses after herpes simplex virus encephalitis. J Neurol. 1985;231(6):307-2. CrossRef
40. Domingues RB, Fink MC, Tsanaclis AM, et al. Diagnosis of herpes simplex encephalitis by magnetic resonance imaging and polymerase chain reaction assay of cerebrospinal fluid. J Neurol Sci. 1998;157(2):148-3. CrossRef
41. Schlesinger Y, Buller RS, Brunstrom JE, et al. Expanded spectrum of herpes simplex encephalitis in childhood. J Pediatr. 1995;126(2):234-1. CrossRef
42. Schmidbauer M, Podreka I, Winberger D, et al. SPECT and MR imaging in herpes simplex encephalitis. J Comput Assist Tomogr. 1991;15(5):811-. CrossRef
43. Schroth G, Gawehn J, Thron A, et al. Early diagnosis of herpes simplex encephalitis by MRI. Neurology. 1987;37(2):179-3. CrossRef
44. Hindmarsh T, Lindqvist M, Olding-Stenkvist E, et al. Accuracy of computed tomography in the diagnosis of herpes simplex encephalitis. Acta Radiol Suppl. 1986;369:192-.
45. Bergey GK, Coyle PK, Krumholz A, et al. Herpes simplex encephalitis with occipital localization. Arch Neurol. 1982;39(5):312-. CrossRef
46. Studahl M, Sk?ldenberg B. Herpes simplex encephalitis and other neurological syndromes caused by herpes simplex virus-1. In: Studahl M, Cinque P, Bergstr?m T, editors. Herpes simplex viruses. New York: Taylor & Francis; 2006. p. 275-16.
47. Brodtkorb E, Lindqvist M, Jonsson M, et al. Diagnosis of herpes simplex encephalitis: a comparison between electro-encephalography and computed tomography findings. Acta Neurol Scand. 1982;66(4):462-1. CrossRef
48. Towne AR, Waterhouse EJ, Boggs JG, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology. 2000;54(2):340-. CrossRef
49. Schloss L, Falk KI, Skoog E, et al. Monitoring of herpes simplex virus DNA types 1 and 2 viral load in cerebrospinal fluid by real-time PCR in patients with herpes simplex encephalitis. J Med Virol. 2009;81(8):1432-. CrossRef
50. Cinque P, Cleator GM, Weber T, et al. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. The EU Concerted Action on Virus Meningitis and Encephalitis. J Neurol Neurosurg Psychiatry. 1996;61(4):339-5. CrossRef
51. National Institute of Allergy and Infectious Diseases (NIAID). Long term treatment of herpes simplex encephalitis (HSE) with valacyclovir [Clinicaltrials.gov identifier NCT00031486]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 2 May 2012.
52. Stahl JP, Mailles A, De Broucker T, et al. Herpes simplex encephalitis and management of acyclovir in encephalitis patients in France. Epidemiol Infect. 2012;140(2):372-1. CrossRef
53. Kamei S, Sekizawa T, Shiota H, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry. 2005;76(11):1544-. CrossRef
54. Martinez-Torres F, et al. Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. BMC Neurol. 2008;29(8):40. CrossRef
55. Sk?ldenberg B, Aurelius E, Hjalmarsson A, et al. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol. 2006;253(2):163-0. CrossRef
56. Tedder DG, Ashley R, Tyler KL, et al. Herpes simplex virus infection as a cause of benign recurrent lymphocytic meningitis. Ann Intern Med. 1994;121(5):334-. CrossRef
57. Bergstr?m T, Vahlne A, Alestig K, et al. Primary and recurrent herpes simplex virus type 2-induced meningitis. J Infect Dis. 1990;162(2):322-0. CrossRef
58. O’Sullivan CE, Aksamit AJ, Harrington JR, et al. Clinical spectrum and laboratory characteristics associated with detection of herpes simplex virus DNA in cerebrospinal fluid. Mayo Clin Proc. 2003;78(11):1347-2. CrossRef
59. Sk?ldenberg B, Jeansson S, Wolontis S. Herpes simplex virus type 2 and acute aseptic meningitis: clinical features of cases with isolation of herpes simplex virus from cerebrospinal fluids. Scand J Infect Dis. 1975;7(4):227-2.
60. Corey L, Adams HG, Brown ZA, et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983;98(6):958-2. CrossRef
61. Aurelius E, Forsgren M, Gille E, et al. Neurologic morbidity after herpes simplex virus type 2 meningitis: a retrospective study of 40 patients. Scand J Infect Dis. 2002;34(4):278-3. CrossRef
62. Terni M, Caccialanza P, Cassai E, et al. Aseptic meningitis in association with herpes progenitalis. N Engl J Med. 1971;285(9):503-. CrossRef
63. Bachmeyer C, de la Blanchardière A, Lepercq J, et al. Recurring episodes of meningitis (Mollaret’s meningitis) with one showing an association with herpes simplex virus type 2. J Infect. 1996;32(3):247-. CrossRef
64. Kallio-Laine K, Sepp?nen M, Kautiainen H, et al. Recurrent lymphocytic meningitis positive for herpes simplex virus type 2. Emerg Infect Dis. 2009;15(7):1119-2. CrossRef
65. Aurelius E, Franzen-R?hl E, Glim?ker M, et al. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomised, controlled trial. Clin Infect Dis. 2012;54(9):1304-3. CrossRef
66. Read S, Kurtz JB. Laboratory diagnosis of common viral infections of the central nervous system by using a single multiplex PCR screening assay. J Clin Microbiol. 1999;37(5):1352-.
67. Brenton DW. Hypoglycorrhachia in herpes simplex type 2 meningitis. Arch Neurol. 1980;37(5):317. CrossRef
68. Sk?ldenberg B, Jeansson S, Wolontis S. Herpes simplex virus type 2 in acute aseptic meningitis. Br Med J. 1973;2(5866):611. CrossRef
69. Kupila L, Vainionp?? R, Vuorinen T, et al. Recurrent lymphocytic meningitis: the role of herpesviruses. Arch Neurol. 2004;61(10):1553-. CrossRef
70. Aurelius E. Neurological disease in herpes simplex virus type 2 (HSV-2) infection. In: Studahl M, Cinque P, Bergstr?m T, editors. Herpes simplex viruses. New York: Taylor & Francis; 2006. p. 317-8.
71. Lycke J, Malmestr?m C, St?hle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother. 2003;47(8):2438-1. CrossRef
72. Bergstr?m T, Alestig K. Treatment of primary and recurrent herpes simplex virus type 2 induced meningitis with acyclovir. Scand J Infect Dis. 1990;22(2):239-0. CrossRef
73. Berger JR. Benign aseptic (Mollaret’s) meningitis after genital herpes. Lancet. 1991;115(1):19-1.
74. Koskiniemi M, Piiparinen H, Rantalaiho T, et al. Acute central nervous system complications in varicella zoster virus infections. J Clin Virol. 2002;25(3):293-01. CrossRef
75. Ziebold C, von Kries R, Lang R, et al. Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics. 2001;108(5):1-.
76. Frenos S, Galli L, Chiappini E, et al. An increasing incidence of chickenpox central nervous system complications in children: what’s happening in Tuscany? J Clin Virol. 2007;38(4):358-1. CrossRef
77. Rack AL, Grote V, Streng A, et al. Neurologic varicella complications before routine immunization in Germany. Pediatr Neurol. 2010;42(1):40-. CrossRef
78. Glaser CA, Gilliam S, Schnurr D, et al. In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998-000. Clin Infect Dis. 2003;36(6):731-2. CrossRef
79. Guess HA, Broughton DD, Melton LJ 3rd, et al. Population-based studies of varicella complications. Pediatrics. 1986;78(4Pt2):723-.
80. Connolly AM, Dodson E, Prensky AL, et al. Course and outcome of acute cerebellar ataxia. Ann Neurol. 1994;35(6):673-.
81. Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry. 2001;71(2):149-4. CrossRef
82. Gilden D, Cohrs RJ, Mahalingam R, et al. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol. 2009;8(8):731-0. CrossRef
83. Ciccone S, Faggioli R, Calzolari F, et al. Stroke after varicella-zoster infection: report of a case and review of the literature. Pediatr Infect Dis J. 2010;29(9):864-. CrossRef
84. Sebire G, Meyer L, Chabrier S. Varicella as a risk factor for cerebral infarction in childhood: a case–control study. Ann Neurol. 1999;45(5):679-0. CrossRef
85. Nagel MA, Cohrs RJ, Mahalingam R, et al. The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology. 2008;70(11):853-0. CrossRef
86. Hattori H, Higuchi Y, Tsuji M. Recurrent strokes after varicella. Ann Neurol. 2000;47(1):136. CrossRef
87. Berger TM, Caduff JH, Gebbers JO. Fatal varicella-zoster antigen-positive giant cell arteritis of the central nervous system. Pediatr Infect Dis J. 2000;19(7):653-. CrossRef
88. Okanishi T, Kondo A, Inoue T, Maegaki Y, Ohno K, Togari H. Bilateral middle cerebral artery infarctions following mild varicella infection: a case report. Brain Dev. 2009;31(1):86-. CrossRef
89. Hokkanen L, Launes J, Poutiainen E, et al. Subcortical type cognitive impairment in herpes zoster encephalitis. J Neurol. 1997;244(4):239-5. CrossRef
90. Aberle SW, Aberle JH, Steininger C, et al. Quantitative real time PCR detection of varicella zoster virus DNA in cerebrospinal fluid in patients with neurological disease. Med Microbiol Immunol. 2005;194(1-):7-2. CrossRef
91. Mathiesen T, Linde A, Olding-Stenkvist E, et al. Antiviral IgM and IgG subclasses in varicella zoster associated neurological syndromes. J Neurol Neurosurg Psychiatry. 1989;52(5):578-2. CrossRef
92. Grahn A, Studahl M, Nilsson S, et al. Varicella-zoster virus (VZV) glycoprotein E is a serological antigen for detection of intrathecal antibodies to VZV in central nervous system infections, without cross-reaction to herpes simplex virus 1. Clin Vaccine Immunol. 2011;18(8):1336-2. CrossRef
93. Pahud BA, Glaser CA, Dekker CL, et al. Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10?years after the introduction of the varicella vaccine. J Infect Dis. 2011;203(3):316-3. CrossRef
94. Haanp?? M, Dastidar P, Weinberg A, et al. CSF and MRI findings in patients with acute herpes zoster. Neurology. 1998;51(5):1405-1. CrossRef
95. Tien RD, Felsberg GJ, Osumi AK. Herpesvirus infections of the CNS: MR findings. Am J Roentgenol. 1993;161(1):167-6. CrossRef
96. Küker W. Cerebral vasculitis: imaging signs revisited. Neuroradiology. 2007;49(6):471-. CrossRef
97. Gnann JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347(5):340-. CrossRef
98. Gilden D. Varicella zoster virus and central nervous system syndromes. Herpes. 2004;11(Suppl 2):89A-4A.
99. Devriese PP, Moesker WH. The natural history of facial paralysis in herpes zoster. Clin Otolaryngol Allied Sci. 1988;13(4):289-8. CrossRef
100. Kinishi M, Amatsu M, Mohri M, et al. Acyclovir improves recovery rate of facial nerve palsy in Ramsay Hunt syndrome. Auris Nasus Larynx. 2001;28(3):223-. CrossRef
101. Furuta Y, Othani F, Mesuda Y, et al. Early diagnosis of zoster sine herpete and antiviral therapy for the treatment of facial palsy. Neurology. 2000;55(5):708-0. CrossRef
102. Murakami S, Hato N, Horiuchi J, et al. Treatment of Ramsay Hunt syndrome with acyclovir-prednisone: significance of early diagnosis and treatment. Ann Neurol. 1997;41(3):353-. CrossRef
103. Uscategui T, Doree C, Chamberlain IJ, et al. Antiviral therapy for Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev. 2008;8(4):CD006851.
104. Uscategui T, Doree C, Chamberlain IJ, et al. Corticosteroids as adjuvant to antiviral treatment in Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev. 2008;16(3):CD006852.
105. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-000. JAMA. 2002;287(5):606-1. CrossRef
106. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-4. CrossRef
107. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, et al. Severe cytomegalovirus infection in apparently immuncompetent patients: a systematic review. Virol J. 2008;5:47. CrossRef
108. Arribas JR, Storch GA, Clifford DB, et al. Cytomegalovirus encephalitis. Ann Intern Med. 1996;125(7):577-7. CrossRef
109. Griffiths P. Cytomegalovirus infection of the central nervous system. Herpes. 2004;11(Suppl 2):95A-04A.
110. Koskiniemi M, Rantalaiho T, Piiparinen H, et al. Infections of the central nervous system of suspected viral origin: a collaborative study from Finland. J Neurovirol. 2001;7(5):400-. CrossRef
111. Yao K, Honarmand S, Espinosa A, et al. Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis. Ann Neurol. 2009;65(3):257-7. CrossRef
112. Ward KN, Leong HN, Nacheva EP, et al. Human herpes virus 6 chromosomal integration in immunocompetent patients results in high levels of viral DNA in blood, sera, and hair follicles. J Clin Microbiol. 2006;44(4):1571-. CrossRef
113. Volpi A. Epstein-Barr virus and human herpesvirus type 8 infections of the central nervous system. Herpes. 2004;11(Suppl 2):120A-A.
114. Caserta MT, Hall CB, Schnabel K, et al. Neuroinvasion and persistence of human herpesvirus 6 in children. J Infect Dis. 1994;170(6):1586-. CrossRef
115. Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children: a prospective study of complications and reactivation. N Engl J Med. 1994;331(7):432-. CrossRef
116. Ljungman P, Singh N. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. J Clin Virol. 2006;37(Suppl. 1):S87-1. CrossRef
117. McCullers JA, Lakeman FD, Whitley RJ. Human herpesvirus 6 is associated with focal encephalitis. Clin Infect Dis. 1995;21(3):571-. CrossRef
118. Studahl M, Hagberg L, Rekabdar E, et al. Hematogenously spread herpesviruses are detected as frequently as neuronally spread herpesviruses in cerebrospinal fluid by polymerase chain reaction assay. Clin Infect Dis. 1999;29(1):216-. CrossRef
119. Davies NW, Brown LJ, Gonde J, et al. Factors influencing PCR detection of viruses in cerebrospinal fluid of patients with suspected CNS infections. J Neurol Neurosurg Psychiatry. 2005;76(1):82-. CrossRef
120. Weber T, Beck R, Stark E, et al. Comparative analysis of intrathecal antibody synthesis and DNA amplification for the diagnosis of cytomegalovirus infection of the central nervous system in AIDS patients. J Neurol. 1994;241(7):407-4. CrossRef
121. Majid A, Galetta SL, Sweeney CJ, et al. Epstein–Barr virus myeloradiculitis and encephalomyeloradiculitis. Brain. 2002;125(Pt 1):159-5. CrossRef
122. Patnaik M, Peter JB. Intrathecal synthesis of antibodies to human herpesvirus 6 early antigen in patients with meningitis/encephalitis. Clin Infect Dis. 1995;21(3):715-. CrossRef
123. Abul-Kasim K, Palm L, Maly P, et al. The neuroanatomic localization of Epstein–Barr virus encephalitis may be a predictive factor for its clinical outcome: a case report and review of 100 cases in 28 reports. J Child Neurol. 2009;24(6):720-. CrossRef
124. Mattes FM, Hainsworth EG, Geretti AM, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis. 2004;189(8):1355-1. CrossRef
125. Demey HE, Martin JJ, Leus RM, et al. Coma as a presenting sign of Epstein–Barr encephalitis. Arch Intern Med. 1988;148(6):1459-1. CrossRef
126. Dellemijn PL, Brandenburg A, Niesters HG, et al. Successful treatment with ganciclovir of presumed Epstein–Barr meningo-encephalitis following bone marrow transplant. Bone Marrow Transplant. 1995;16(2):311-.
127. Straus SE, Cohen JI, Tosato G, et al. NIH conference. Epstein–Barr virus infections: biology, pathogenesis and management. Ann Intern Med. 1993;118(1):45-8. CrossRef
128. Troy SB, Blackburn BG, Yeom K, et al. Severe encephalomyelitis in an immunocompetent adult with chromosomally integrated human herpesvirus 6 and clinical response to treatment with foscarnet plus ganciclovir. Clin Infect Dis. 2008;47(12):e93-. CrossRef
129. Birnbaum T, Padovan CS, Sporer B, et al. Severe meningoencephalitis caused by human herpesvirus 6 type B in an immunocompetent woman treated with ganciclovir. Clin Infect Dis. 2005;40(6):887-. CrossRef
130. Zerr DM, Gupta D, Huang ML, et al. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(3):309-7. CrossRef
131. P?hlmann C, Schetelig J, Reuner U, et al. Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient. Clin Infect Dis. 2007;44(12):e118-0. CrossRef
132. Astriti M, Zeller V, Boutolleau D, et al. Fatal HHV-6 associated encephalitis in an HIV-1 infected patient treated with cidofovir. J Infect. 2006;52(4):237-2. CrossRef
133. Gunther G, Haglund M, Lindquist L, et al. Tick-bone encephalitis in Sweden in relation to aseptic meningo-encephalitis of other etiology: a prospective study of clinical course and outcome. J Neurol. 1997;244(4):230-. CrossRef
134. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-8: a prospective study of 656 patients. Brain. 1999;122(Pt 11):2067-8. CrossRef
135. Mickiene A, Laiskonis A, Gunther G, et al. Tickborne encephalitis in an area of high endemicity in Lithuania: disease severity and long-term prognosis. Clin Infect Dis. 2002;35(6):650-. CrossRef
136. Ecker M, Allison SL, Meixner T, et al. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J Gen Virol. 1999;80(Pt 1):179-5.
137. Holzmann H, Vorobyova MS, Ladyzhenskaya IP, et al. Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes. Vaccine. 1992;10(5):345-. CrossRef
138. Holmgren EB, Forsgren M. Epidemiology of tick-borne encephalitis in Sweden 1956-989: a study of 1116 cases. Scand J Infect Dis. 1990;22(3):287-5. CrossRef
139. Haglund M, Forsgren M, Lindh G, et al. A 10-year follow-up study of tick-borne encephalitis in the Stockholm area and a review of the literature: need for a vaccination strategy. Scand J Infect Dis. 1996;28(3):217-4. CrossRef
140. Puchhammer-Stockl E, Kunz C, Mandl CW, et al. Identification of tick-borne encephalitis virus ribonucleic acid in tick suspensions and in clinical specimens by a reverse transcription-nested polymerase chain reaction assay. Clin Diagn Virol. 1995;4(4):321-. CrossRef
141. Saksida A, Duh D, Lotric-Furlan S, et al. The importance of tick-borne encephalitis virus RNA detection for early differential diagnosis of tick-borne encephalitis. J Clin Virol. 2005;33(4):331-. CrossRef
142. Andersson CR, Vene S, Insulander M, et al. Vaccine failures after active immunisation against tick-borne encephalitis. Vaccine. 2010;28(16):2827-1. CrossRef
143. Stiasny K, Holzmann H, Heinz FX. Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs. Vaccine. 2009;27(50):7021-. CrossRef
144. Lorenzl S, Pfister HW, Padovan C, et al. MRI abnormalities in tick-borne encephalitis. Lancet. 1996;347(9002):698-. CrossRef
145. Marjelund S, Tikkakoski T, Tuisku S, et al. Magnetic resonance imaging findings and outcome in severe tick-borne encephalitis: report of four cases and review of the literature. Acta Radiol. 2004;45(1):88-4. CrossRef
146. Waldvogel K, Bossart W, Huisman T, et al. Severe tick-borne encephalitis following passive immunisation. Eur J Pediatr. 1996;155(9):775-. CrossRef
147. Broker M, Kollaritsch H. After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment. Vaccine. 2008;26(7):863-. CrossRef
148. Stefanoff P, Polkowska A, Giambi C, et al. Reliable surveillance of tick-borne encephalitis in European countries is necessary to improve the quality of vaccine recommendations. Vaccine. 2011;29(6):1283-. CrossRef
149. Heinz FX, Holzmann H, Essl A, et al. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine. 2007;25(43):7559-7. CrossRef
150. Weinberger B, Keller M, Fischer KH, et al. Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50-0?years. Vaccine. 2010;28(20):3511-. CrossRef
151. Hainz U, Jenewein B, Asch E, et al. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine. 2005;23(25):3232-. CrossRef
152. Loew-Baselli A, Poellabauer EM, Pavlova BG, et al. Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5?ml in adults aged 18-7?years. Hum Vaccin. 2009;5(8):551-. CrossRef
153. Loew-Baselli A, Konior R, Pavlova BG, et al. Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies. Vaccine. 2006;24(24):5256-3. CrossRef
154. Zent O, Jilg W, Plentz A, et al. Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule. Vaccine. 2003;21(32):4655-0. CrossRef
155. Beran J, Douda P, Gniel D, et al. Long-term immunity after vaccination against tick-borne encephalitis with encepur using the rapid vaccination schedule. In J Med Microbiol. 2004;293(Suppl 37):130-.
156. Sch?ndorf I, Beran J, Cizkova D, et al. Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine. 2007;25(8):1470-. CrossRef
157. Stiasny K, Aberle JH, Keller M, et al. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS One. 2012;7(3):e34145. CrossRef
158. Lee BE, Davies HD. Aseptic meningitis. Curr Opin Infect Dis. 2007;20(3):272-. CrossRef
159. Ropka SL, Jubelt B. Enteroviruses. In: Nath A, Berger JR, editors. Clinical neurovirology. New York: Marcel-Dekker; 2003. p. 359-7.
160. Sawyer MH, Rotbart HA. Viral meningitis and aseptic meningitis syndrome. In: Scheld WM, Whitley RJ, Marra CM, editors. Infections of the central nervous system. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 75-3.
161. Rotbart HA. Enteroviral infections of central nervous system. Clin Infect Dis. 1995;20(4):971-1. CrossRef
162. Polio Global Eradication Initiative. Wild poliovirus weekly update. http://www.polioeradication.org/. Accessed 8 Feb 2012.
163. Ho M. Enterovirus 71: the virus, its infections and outbreaks. J Microbiol Immunol Infect. 2000;33(4):205-6.
164. Kelly H, Brussen KA, Lawrence A, et al. Polioviruses and other enteroviruses isolated from faecal samples of patients with acute flaccid paralysis in Australia, 1996-004. J Paediatr Child Health. 2006;42(6):370-. CrossRef
165. Glim?ker M, Johansson B, Olcen P, et al. Detection of enteroviral RNA by polymerase chain reaction in cerebrospinal fluid from patients with aseptic meningitis. Scand J Infect Dis. 1993;25(5):547-7. CrossRef
166. Mohamed N, Elfaitouri A, Fohlman J, et al. A sensitive and quantitative single-tube real-time reverse transcriptase-PCR for detection of enteroviral RNA. J Clin Virol. 2004;30(2):150-. CrossRef
167. Sato M, Hosoya M, Honzumi K, et al. Cytokine and cellular inflammatory sequence in enteroviral meningitis. Pediatrics. 2003;112(5):1103-. CrossRef
168. King RL, Lorch SA, Cohen DM, et al. Routine cerebrospinal fluid enterovirus polymerase chain reaction testing reduces hospitalization and antibiotic use for infants 90?days of age or younger. Pediatrics. 2007;120(3):489-6. CrossRef
169. Nigrovic LE, Chiang VW. Cost analysis of enteroviral polymerase chain reaction in infants with fever and cerebrospinal fluid pleocytosis. Arch Pediatr Adolesc Med. 2000;154(8):817-1. CrossRef
170. Ninove L, Tan C, Nougairede A, et al. Impact of diagnostic procedures on patient management and hospitalization cost during the 2000 and 2005 enterovirus epidemics in Marseilles, France. Clin Microbiol Infect. 2010;16(6):651-. CrossRef
171. Fauquet C, Mayo M, Maniloff J, et al., editors. Virus taxonomy: eighth report of the International Committee on Taxonomy of Viruses. San Diego: Elsevier Inc.; 2005.
172. ICTVdB management. 00.052. Picornaviridae. In: Büchen-Osmond C, editor. ICTVdB: the universal virus database, version 4. New York: Columbia University; 2006.
173. Glim?ker M, Samuelson A, Magnius L, et al. Early diagnosis of enteroviral meningitis by detection of specific IgM antibodies with a solid-phase reverse immunosorbent test (SPRIST) and m-capture EIA. J Med Virol. 1992;36(3):193-01. CrossRef
174. Elfaitouri A, Mohamed N, Fohlman J, et al. Quantitative PCR-enhanced immunoassay for measurement of enteroviral immunoglobulin M antibody and diagnosis of aseptic meningitis. Clin Diagn Lab Immunol. 2005;12(2):235-1.
175. Desmond RA, Accortt NA, Talley L, et al. Enteroviral meningitis: natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother. 2006;50(7):2409-4. CrossRef
176. Abzug MJ, Cloud G, Bradley J, Sánchez PJ, Romero J, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, et al. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J. 2003;22(4):335-1.
177. Li ZH, Li CM, Ling P, et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008;197(6):854-. CrossRef
178. Quartier P, Foray S, Casanova JL, et al. Enteroviral meningoencephalitis in X-linked agammaglobulinemia: intensive immunoglobulin therapy and sequential viral detection in cerebrospinal fluid by polymerase chain detection. Pediatr Infect Dis J. 2000;19(11):1106-. CrossRef
179. Abzug MJ, Keyserling HL, Lee ML, et al. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis. 1995;20(5):1201-. CrossRef
180. Wang SM, Lei HY, Huang MC, et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol. 2006;37(1):47-2. CrossRef
181. McMinn PC. Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol. 2012;2(2):199-05. CrossRef
182. Mizuguchi M, Abe J, Mikkaichi K, et al. Acute necrotising encephalopathy of childhood: a new syndrome presenting with multifocal, symmetric brain lesions. J Neurol Neurosurg Psychiatry. 1995;58(5):555-1. CrossRef
183. Kirton A, Busche K, Ross C, et al. Acute necrotizing encephalopathy in caucasian children: two cases and review of the literature. J Child Neurol. 2005;20(6):527-2.
184. Mastroyianni SD, Gionnis D, Voudris K, et al. Acute necrotizing encephalopathy of childhood in non-Asian patients: report of three cases and literature review. J Child Neurol. 2006;21(10):872-. CrossRef
185. Fasano A, Natoli GF, Cianfoni A, et al. Acute necrotizing encephalopathy: a relapsing case in a European adult. J Neurol Neurosurg Psychiatry. 2008;79(2):227-. CrossRef
186. Amin R, Ford-Jones E, Richardson SE, et al. Acute childhood encephalitis and encephalopathy associated with influenza: a prospective 11-year review. Pediatr Infect Dis J. 2008;27(5):390-. CrossRef
187. Fowler A, St?dberg T, Eriksson M, et al. Childhood encephalitis in Sweden: etiology, clinical presentation and outcome. Eur J Paediatr Neurol. 2008;12(6):484-0. CrossRef
188. Surana P, Tang S, McDougall M, et al. Neurological complications of pandemic influenza A H1N1 2009 infection: European case series and review. Eur J Pediatr. 2011;170(8):1007-5. CrossRef
189. Studahl M, Linde A. Influenza and CNS complications. In: Nath A, Berger JR, editors. Clinical neurovirology. 1st ed. New York: Marcel-Dekker; 2003. p. 453-8.
190. Fujimoto S, Kobayashi M, Uemura O, et al. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet. 1998;352(9131):873-. CrossRef
191. Kimura S, Ohtuki N, Nezu A, et al. Clinical and radiological variability of influenza-related encephalopathy or encephalitis. Acta Paediatr Jpn. 1998;40(3):264-0. CrossRef
192. Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brain Dev. 2009;31(7):521-. CrossRef
193. Studahl M. Influenza virus and CNS manifestations. J Clin Virol. 2003;28(3):225-2. CrossRef
194. Wang GF, Li W, Li K. Acute encephalopathy and encephalitis caused by influenza virus infection. Curr Opin Neurol. 2010;23(3):305-1. CrossRef
195. Falagas ME, Koletsi PK, Vouloumanou EK, et al. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(7):1330-6. CrossRef
196. Jhee SS, Yen M, Ereshefsky L, et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother. 2008;52(10):3687-3. CrossRef
197. Kornhuber J, Quack G, Danysz W, et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology. 1995;34(7):713-1. CrossRef
198. Munakata M, Kato R, Yokoyama H, et al. Combined therapy with hypothermia and anticytokine agents in influenza A encephalopathy. Brain Dev. 2000;22(6):373-. CrossRef
199. Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;7:CD001269.
200. Sugaya N, Takeuchi Y. Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan. Clin Infect Dis. 2005;41(7):939-7. CrossRef
201. Miller HG, Stanton JB, Gibbons JL. Para-infectious encephalomyelitis and related syndromes: a critical review of the neurological complications of certain specific fevers. Q J Med. 1956;25(100):427-05.
202. Baba Y, Tsuboi Y, Inoue H, et al. Acute measles encephalitis in adults. J Neurol. 2006;253(1):121-. CrossRef
203. Aicardi J, Goutieres F, Arsenio-Nunes ML, et al. Acute measles encephalitis in children with immunosuppression. Pediatrics. 1977;59(2):232-.
204. Norrby E, Kristensson K. Measles virus in the brain. Brain Res Bull. 1997;44(3):213-0. CrossRef
205. Gutierrez J, Issacson RS, Koppel BS. Subacute sclerosing panencephalitis: an update. Dev Med Child Neurol. 2010;52(10):901-. CrossRef
206. Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008;371(9616):932-4. CrossRef
207. Koskiniemi M, Donner M, Pettay O. Clinical appearance and outcome in mumps encephalitis in children. Acta Paediatr Scand. 1983;72(4):603-. CrossRef
208. Griffin DE. Measles and rubella. In: Scheld WM, Whitley RJ, Marra CM, editors. Infections of the central nervous system. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 111-2.
209. Nath A. Rubella. In: Nath A, Berger JR, editors. Clinical neurovirology. 1st ed. London: Taylor and Francis; 2003. p 447-2.
210. Weissbrich B, Schneider-Schaulies J, ter Meulen V. Measles and its neurological complications. In: Nath A, Berger JR, editors. Clinical neurovirology. 1st ed. London: Taylor and Francis; 2003. p 401-0.
211. Health Protection Agency UK. Investigation of viral encephalitis and meningitis. National Standard Method QSOP. 2004;48(2):1-9.
212. Garg RK. Subacute sclerosing panencephalitis. J Neurol. 2008;255(12):1861-1. CrossRef
213. Baum SG, Litman N. Mumps virus. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill-Livingstone; 2000. p. 1776-1.
214. Lau KK, Lai ST, Lai JY, et al. Acute encephalitis complicating rubella. Hong Kong Med J. 1998;4(3):325-.
215. Bosma TJ, Corbett KM, O′Shea S, et al. PCR for detection of rubella virus RNA in clinical samples. J Clin Microbiol. 1995;33(5):1075-.
216. Schneider-Schaulies J, ter Meulen V, Schneider-Schaulies S. Measles infection of the central nervous system. J Neurovirol. 2003;9(2):247-2.
217. Sugita K, Ando M, Minamitani K, et al. Magnetic resonance imaging in a case of mumps postinfectious encephalitis with asymptomatic optic neuritis. Eur J Pediatr. 1991;150(11):773-. CrossRef
218. Liebert UG. Measles virus infections of the central nervous system. Intervirology. 1997;40(2-):176-4. CrossRef
219. Wetzel K, Asholt I, Herrmann E, et al. Good cognitive outcome of patients with herpes zoster encephalitis: a follow-up study. J Neurol. 2002;249(11):1612-. CrossRef
220. Adour KK. Otological complications of herpes zoster. Ann Neurol. 1994;35 Suppl:S62-.
221. Wagstaff AJ, Faulds D, Goa KL, et al. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47(1):153-05. CrossRef
222. Gnann JW Jr. Varicella zoster virus: atypical presentations and unusual complications. J Infect Dis. 2002;186(Suppl. 1):S91-. CrossRef
223. Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996;2282:341-. CrossRef
224. Wood MJ, Shukla S, Fiddian AP, et al. Treatment of acute herpes zoster: effect of early (<48?h) versus late (48-2?h) therapy with acyclovir and valacyclovir on prolonged pain. J Infect Dis. 1998;178(Suppl. 1):S81-. CrossRef
225. Gilden DH, Mahalingam R, Cohrs RJ, et al. Herpesvirus infections of the central nervous system. Nat Clin Pract Neurol. 2007;3(2):82-4. CrossRef
226. Sekiyama T, Hatsua S, Tanaka Y, et al. Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses. J Med Chem. 1998;41(8):1284-8. CrossRef
227. Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001;108(2):230-. CrossRef
228. Bean B, Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis. 1985;151(2):362-. CrossRef
229. Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999;106(4):45-5. CrossRef
230. Hellden A, Lycke J, Vander T, et al. The acyclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during acyclovir and valaciclovir treatment. J Antimicrob Chemother. 2006;57(5):945-. CrossRef
231. Weller S, Blum R, Doucette M, et al. Pharmacokinetics of the acyclovir prodrug valacyclovir after escalating single-and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54(6):595-05. CrossRef
232. Pouplin T, Pouplin JN, Van Toi P, et al. Valacyclovir for herpes simplex encephalitis. Antimicrob Agents Chemother. 2011;55(7):3624-. CrossRef
233. Frank KB, Chiou JF, Cheng YC. Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl) guanine triphosphate. J Biol Chem. 1984;259(3):1566-.
234. Russler SK, Tapper MA, Carrigan DR. Susceptibility of human herpesvirus 6 to acyclovir and ganciclovir. Lancet. 1989;2(8659):382. CrossRef
235. Crumpacker CS. Ganciclovir. N Engl J Med. 1996;335(10):721-. CrossRef
236. Cinque P, Cleator GM, Weber T, et al. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. J Neurovirol. 1998;4(1):120-2. CrossRef
237. Brown F, Banken L, Saywell K, et al. Pharmacokinetics of valganciclovir and ganciuclovir following multiple oral dosages of valganciclovir in HIV-and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37(2):161-6. CrossRef
238. Martin DF, Sierra-Mader J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346(15):1119-6. CrossRef
239. Gerard L, Salmon-Ceron D. Pharmacology and clinical use of foscarnet. Int J Antimicrob Agents. 1995;5(4):209-7. CrossRef
240. Jabs DA, Enger C, Forman M, The cytomegalovirus retinitis and viral resistance study group, et al. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrob Agents Chemother. 1998;42(9):2240-.
241. Peters M, Timm U, Schürmann D, et al. Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone: a case report and review of the literature. Clin Invest. 1992;70(5):456-. CrossRef
242. Peavear DC, Tull TM, Seipel ME, et al. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999;43(9):2109-5.
243. L′Huillier AG, Lorenzini KI, Crisinel PA, et al. Polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia. Pharmacogenomics. 2011;12(10):1493-01. CrossRef
244. Field HJ, Darby G, Wildy P. Isolation and characterization of acyclovir resistant mutants of herpes simplex virus. J Gen Virol. 1980;49(1):115-4. CrossRef
245. Pottage JC Jr, Kessler HA. Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis. 1995;4(3):115-4.
246. Biron KK, Fyfe JA, Noblin JE, et al. Selection and preliminary characterization of acyclovir resistant mutants of varicella zoster virus. Am J Med. 1982;73(1A):383-. CrossRef
247. Bacon TH, Boon RJ, Schultz M, et al. Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis. Antimicrob Agents Chemother. 2002;46:3042-. CrossRef
248. Grey F, Sowa M, Collins P, et al. Characterization of a neurovirulent acyclovir-resistant variant of herpes simplex virus. J Gen Virol. 2003;84:1403-0. CrossRef
249. Schulte EC, Sauerbrei A, Hoffman D, et al. Acyclovir resistance in herpes simplex encephalitis. Ann Neurol. 2010;67(6):830-. CrossRef
250. Kakiuchi S, Nonoyama S, Wakamatsu H, et al. Neonatal herpes encephalitis caused by a virologically confirmed acyclovir resistant herpes simplex virus type 1. J Clin Microbiol. 2013;51(1):356-.
251. Brink AA, van Gelder M, Wolffs PF, et al. Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnostics. Clin Infect Dis. 2011;52(8):982-. CrossRef
252. Aurelius E, Forsgren M, Sk?ldenberg B, et al. Persistent intrathecal immune activation in patients with herpes simplex encephalitis. J Infect Dis. 1993;168(5):1248-2. CrossRef
253. Aurelius E, Andersson B, Forsgren M, et al. Cytokines and other markers of intrathecal immune response in patients with herpes simplex encephalitis. J Infect Dis. 1994;170(3):678-1. CrossRef
254. Thompson KA, Blessing WW, Wesselingh SL. Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis. J Neurovirol. 2000;6(1):25-2. CrossRef
255. Meyding-Lamade UK, Oberlinner C, Rau PR, et al. Experimental herpes simplex virus encephalitis: a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities. J Neurovirol. 2003;9(1):118-5.
256. Mailles A, De Broucker T, Costanzo P, et al. Long-term outcome of patients presenting with acute infectious encephalitis of various causes in France. Clin Infect Dis. 2012;54(10):1455-4. CrossRef
257. De Broucker T, Mailles A, Chabrier S, et al. Acute varicella zoster encephalitis without evidence of primary vasculopathy in a case series of 20 patients. Clin Microbiol Infect. 2012;18(8):808-9. CrossRef - 作者单位：Marie Studahl (1) (7)
Lars Lindquist (2)
Britt-Marie Eriksson (3)
G?ran Günther (3)
Malin Bengner (4)
Elisabeth Franzen-R?hl (8)
Jan Fohlman (5)
Tomas Bergstr?m (6)
Elisabeth Aurelius (8)
1. Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
7. Department of Infectious Diseases, Sahlgrenska University Hospital, 416 85, G?teborg, Sweden
2. Institution of Medicine, Huddinge, Unit for Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
3. Section of Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
4. Infectious Diseases, Ryhov County Hospital, J?nk?ping, Sweden
8. Institution of Medicine, Solna, Unit for Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
5. R & D Centre and Department of Infectious Diseases, Central Hospital, V?xj?, Sweden
6. Department of Virology, University of Gothenburg, Gothenburg, Sweden
文摘
Patients with viral infections of the central nervous system (CNS) may present with a variety of neurological symptoms, most commonly dominated by either encephalitis or meningitis. The aetiological panorama varies in different parts of the world as well as over time. Thus, virological first-line diagnostics must be adapted to the current epidemiological situation and to the individual patient history, including recent travels. This review focuses on the diagnostics and treatment of viral CNS infections in the immunocompetent host from a Northern European perspective. Effective vaccines are available for viruses such as poliovirus and tick-borne encephalitis virus (TBEV) and for the childhood diseases morbilli (measles), rubella (German measles), parotitis (mumps) and varicella (chickenpox). However, cases do appear due to suboptimal immunization rates. In viral CNS infections, epidemiological surveillance is essential for establishing preventive strategies and for detecting emerging viruses. Knowledge of the possibilities and limitations of diagnostic methods for specific viral CNS infections is vital. A positive cerebral spinal fluid (CSF) polymerase chain reaction (PCR) finding is usually reliable for aetiological diagnosis. The demonstration of intrathecal antibody synthesis is useful for confirming the aetiology in a later stage of disease, hitherto sufficiently evaluated in herpes simplex encephalitis (HSE) and tick-borne encephalitis (TBE). Despite improved virological and differential diagnostic methods, aetiology remains unknown in about half of the cases with suspected viral encephalitis. Antiviral treatment is available chiefly for infections caused by herpesviruses, and acyclovir (aciclovir) is the drug of choice for empirical therapy in suspected viral encephalitis. However, randomized, controlled antiviral trials have only been conducted for HSE, while such studies are lacking in other viral CNS infections. Viral cytolysis and immune-mediated mechanisms may contribute to varying extents to neurological damage. Although the brain damage is believed to depend, to a varying degree, on the intrathecal host immune response, the use of corticosteroids in viral CNS infections is scarcely studied, as is specific treatment for neuroinflammation. Improved antiviral and immunomodulating treatment is desirable. Since neurological sequelae are still abundant, follow-up after severe viral CNS disease must include a neuropsychological assessment and an individually adapted rehabilitation plan.